partitioning of the chromosomal DNA during bacterial cell division, however, the exact mechanism by which trovafloxacin inhibits this enzyme is not known.
The most dangerous adverse effect related to trovafloxacin is hepatotoxicity. Others include: dizziness (2-11%); nausea (4-8%); headache (1-5%); lightheadedness (1-4%); pruritus (1-2%); abdominal pain (1%); diarrhea (1%); inflammation (1%); injection site reaction (1%); vaginitis (1%) The following effects are seen in <1%: Phototoxicity; Convulsions; Dyskinesia; Pseudomembranous colitis; Allergic/anaphylactoid reaction; Tendonitis; Bronchospasm; Interstitial nephritis; Anaphylaxis; Hepatic necrosis; Pancreatitis.
Pregnancy & Lactation:
Pregnancy Category is C. Drug is excreted in breast milk
Half-life elimination is 9-12 hrs. Protein binding is 76% and bioavailability is 88%. Time to peak, serum: oral: within 2 hr. Distribution: concentration in most tissues greater than plasma or serum. Metabolism: hepatic. Excretion: feces (43% as unchanged drug); urine (6% as unchanged drug).
For adults: Community-acquired pneumonia: Oral, I.V.: 200 mg/day for 7-14 days. Complicated intra-abdominal infections, including postsurgical infections or gynecologic and pelvic infections: I.V.: 300 mg as a single dose followed by 200 mg/day orally for a total duration of 7-14 days. Skin and skin structure infections, complicated, including diabetic foot infections: Oral, I.V.: 200 mg/day for 10-14 days.
Dosage adjustment in hepatic impairment:
Mild to moderate cirrhosis:
Initial dose for normal hepatic function: 300 mg I.V.; 200 mg I.V. or oral; 100 mg oral.
Reduced dose: 200 mg I.V.; 100 mg I.V. or oral; 100 mg oral. Severe cirrhosis: No data available.
Injection, as mesylate (alatrofloxacin): 5 mg/mL (40 mL, 60 mL).
Tablet, as mesylate (trovafloxacin): 100 mg, 200 mg.
Trovafloxacin contains a cyclopropylamine moiety which has a potential to be oxidized to reactive intermediate(s). P450s with heme-iron center and myeloperoxidase (MPO) generating hypochlorous acid (HClO) in the presence of